Previous 10 | Next 10 |
home / stock / tpst / tpst articles
Tempest Therapeutics Inc (NASDAQ: TPST) shares are trading lower Thursday. The company sold shares as part of a previously announced offe...
Major U.S. stock indices ended in the green on Wednesday, with the Nasdaq Composite marking notable gains of nearly 100 points. The Dow also ended ...
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Wednesday. The Dow traded down 0....
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Wednesday. The Dow traded down 0.19% to 33,674.6...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the D...
Bloomberg Google's AI Dilemma - Bard's Promise Versus Ethical Concerns Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google a...
Tempest Therapeutics Inc (NASDAQ: TPST) released new and updated results from the planned data analysis of an ongoing Phase 1b/2 study of TPST...
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares rose 279.8% to $0.9115 in pre-market trading, after the company announced it plans to rep...
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday. Immunic, Inc. (NASDAQ: IMUX)...
News, Short Squeeze, Breakout and More Instantly...
Tempest Therapeutics Inc. Company Name:
TPST Stock Symbol:
NASDAQ Market:
Tempest Therapeutics Inc. Website:
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves ...
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global ran...